Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model

BACKGROUND: Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient‐derived tumor xenograft (PDTX) models of ora...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Cheng‐Yu, Lin, Chih‐Kung, Hsieh, Cheng‐Chih, Tsao, Chang‐Huei, Lin, Chun‐Shu, Peng, Bo, Chen, Yen‐Tzu, Ting, Chun‐Chieh, Chang, Wei‐Chin, Lin, Gu‐Jiun, Sytwu, Huey‐Kang, Chen, Yuan‐Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590365/
https://www.ncbi.nlm.nih.gov/pubmed/30537218
http://dx.doi.org/10.1002/hed.25554
_version_ 1783429542953615360
author Yang, Cheng‐Yu
Lin, Chih‐Kung
Hsieh, Cheng‐Chih
Tsao, Chang‐Huei
Lin, Chun‐Shu
Peng, Bo
Chen, Yen‐Tzu
Ting, Chun‐Chieh
Chang, Wei‐Chin
Lin, Gu‐Jiun
Sytwu, Huey‐Kang
Chen, Yuan‐Wu
author_facet Yang, Cheng‐Yu
Lin, Chih‐Kung
Hsieh, Cheng‐Chih
Tsao, Chang‐Huei
Lin, Chun‐Shu
Peng, Bo
Chen, Yen‐Tzu
Ting, Chun‐Chieh
Chang, Wei‐Chin
Lin, Gu‐Jiun
Sytwu, Huey‐Kang
Chen, Yuan‐Wu
author_sort Yang, Cheng‐Yu
collection PubMed
description BACKGROUND: Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient‐derived tumor xenograft (PDTX) models of oral squamous cell carcinoma (OSCC). METHODS: The expression of DcR3 was evaluated through immunohistochemistry, and correlations were examined using clinical variables. The effects of TPL on the expression of DcR3 and cell proliferation were investigated in OSCC cell lines and in PDTX models. RESULTS: DcR3 overexpression was associated with overall survival and tumor size. TPL significantly decreased tumor growth. Moreover, TPL inhibited the expression of metastasis‐associated protein 1 (MTA1), a transcription factor for DcR3 in vivo, in vitro, and in PDTX models. CONCLUSION: TPL appeared to exert anticancer effects by repressing DcR3 and MTA1 in vitro, in vivo, and in PDTX models.
format Online
Article
Text
id pubmed-6590365
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65903652019-07-08 Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model Yang, Cheng‐Yu Lin, Chih‐Kung Hsieh, Cheng‐Chih Tsao, Chang‐Huei Lin, Chun‐Shu Peng, Bo Chen, Yen‐Tzu Ting, Chun‐Chieh Chang, Wei‐Chin Lin, Gu‐Jiun Sytwu, Huey‐Kang Chen, Yuan‐Wu Head Neck Original Articles BACKGROUND: Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient‐derived tumor xenograft (PDTX) models of oral squamous cell carcinoma (OSCC). METHODS: The expression of DcR3 was evaluated through immunohistochemistry, and correlations were examined using clinical variables. The effects of TPL on the expression of DcR3 and cell proliferation were investigated in OSCC cell lines and in PDTX models. RESULTS: DcR3 overexpression was associated with overall survival and tumor size. TPL significantly decreased tumor growth. Moreover, TPL inhibited the expression of metastasis‐associated protein 1 (MTA1), a transcription factor for DcR3 in vivo, in vitro, and in PDTX models. CONCLUSION: TPL appeared to exert anticancer effects by repressing DcR3 and MTA1 in vitro, in vivo, and in PDTX models. John Wiley & Sons, Inc. 2018-12-10 2019-05 /pmc/articles/PMC6590365/ /pubmed/30537218 http://dx.doi.org/10.1002/hed.25554 Text en © 2018 The Authors. Head & Neck published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Yang, Cheng‐Yu
Lin, Chih‐Kung
Hsieh, Cheng‐Chih
Tsao, Chang‐Huei
Lin, Chun‐Shu
Peng, Bo
Chen, Yen‐Tzu
Ting, Chun‐Chieh
Chang, Wei‐Chin
Lin, Gu‐Jiun
Sytwu, Huey‐Kang
Chen, Yuan‐Wu
Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title_full Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title_fullStr Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title_full_unstemmed Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title_short Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
title_sort anti‐oral cancer effects of triptolide by downregulation of dcr3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590365/
https://www.ncbi.nlm.nih.gov/pubmed/30537218
http://dx.doi.org/10.1002/hed.25554
work_keys_str_mv AT yangchengyu antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT linchihkung antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT hsiehchengchih antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT tsaochanghuei antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT linchunshu antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT pengbo antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT chenyentzu antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT tingchunchieh antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT changweichin antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT lingujiun antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT sytwuhueykang antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel
AT chenyuanwu antioralcancereffectsoftriptolidebydownregulationofdcr3invitroinvivoandinpreclinicalpatientderivedtumorxenograftmodel

Ejemplares similares